A New Standard of Care for Head and Neck Cancer?
Recently, the FDA approved pembrolizumab for adults with resectable locally advanced head and neck squamous cell carcinoma (HNSCC). The treatment is approved as a neoadjuvant
August 22, 2025
No Comments